Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Top 20 respiratory brands in the U.S. based on revenue in 2016 (in million U.S. dollars)

Exclusive Premium Statistic

Revenue of top 20 respiratory brands in the U.S. 2016 This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Product name (company)Revenue in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

Get a Premium Account for unrestrained access.
Benefits of our Premium membership:

  • Access to all Premium statistics
  • Download as XLS, PNG and PDF
  • Detailed source and background information
Premium Account
$49 per month*
(billed annually)
*Single license

Access to this and all other statistics on 80,000 topics from

$588 / Year

View price details

© Statista 2018

Download Settings Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Description Source More information
This statistic displays the top 20 brands for respiratory diseases based on revenue in the United States in 2016. In that year, Merck's Dulera generated some 412 million U.S. dollars in revenues. Thus, Dulera was ranked 15th among respiratory products in the United States.
Top respiratory products

Spiriva from Boehringer Ingelheim and Symbicort Turbohaler from AstraZeneca are among the top respiratory brands in the United States, generating 1.87 billion and 1.24 billion U.S. dollars in 2016. The United States accounted for around half of the world’s pharmaceutical top product revenues.

Spiriva is a tiotropium bromide that is used for chronic obstructive pulmonary disease (COPD). This drug is a muscarinic receptor antagonist which reduces smooth muscle contraction and mucus secretion in order to dilate the bronchials. Symbicort is used in the treatment of asthma and COPD, as well as chronic bronchitis and emphysema. COPD caused 5.6 percent of deaths worldwide in 2012. It is an obstructive lung disease, where airflow degenerates over time. It is primarily caused by smoking. Currently, there is no cure for the disease, but there are medications and preventative measures that can help minimize symptoms. Long-term exposure to smoking can perpetuate COPD symptoms. The respiratory therapy market is expected to reach up to 5 billion U.S. dollars in the so called pharmerging markets by 2018.
Show more
Release date
April 2017
Region
United States
Survey time period
2016

Statista Accounts: Access All Statistics. Starting from $588 / Year

Leading companies trust Statista:

Related Studies: Available to Download in PDF or PPTX Format

Top pharmaceutical drugs

All Information
in one Presentation

Top pharmaceutical drugs

Everything On "Top pharmaceutical drugs" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.

Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.
Marlene Greenfield

Marlene Greenfield
Vice President, Hearst Magazines

Statistics on "Asthma"

  • Global context
The most important statistics
  • Prevalence and death rates
The most important statistics
  • Regions and states
The most important statistics
  • Doctors and hospitals
The most important statistics
  • Medication
The most important statistics
  • Risks
The most important statistics
Statista for your company

Saves time and money: instant access to this and 1 million more statistics.
Access to dossiers, industry reports and many other studies.

Need help with using Statista for your research? Tutorials and first steps

Further Content: Statistics, Studies, and Topic Pages

Statistics on the topic

Topics

About Statista

Learn more about how Statista can support your business.

Request webinar
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.